Improved Treatment Persistence With New-Generation Beta Blockers

This article originally appeared here.
Share this content:
Notable improvement seen with carvedilol and nebivolol, but not betaxolol.
Notable improvement seen with carvedilol and nebivolol, but not betaxolol.

(HealthDay News) -- Persistent use of antihypertensive treatments is greater with the new generation of beta-blockers, compared to atenolol, according to a study published in the August issue of Cardiovascular Therapeutics.

Yun Jung Choi, from Hanyang University in South Korea, and colleagues analyzed persistent use of antihypertensive medications among 9,978 patients (≥18 years) with newly diagnosed hypertension in 2012. The participants were without hypertension-related complication and had initiated treatment with beta-blocker monotherapy.

The researchers found that the rate of treatment persistence was higher in the non-atenolol group (P < 0.0001), and time to treatment discontinuation was earlier in the atenolol group (P < 0.0001). Compared to atenolol, new generation beta-blockers demonstrated a lower risk of treatment discontinuation (hazard ratio [HR], 0.91), with notable improvement seen with carvedilol and nebivolol (HRs, 0.74 and 0.79, respectively). Betaxolol showed a substantially greater hazard for discontinuation versus atenolol.

"This study demonstrated meaningful improvement in treatment persistence with new generation beta-blockers compared to atenolol, with betaxolol as exception," the authors write.


1. Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study. Cardiovascular Therapeutics. 2016 Jul 6. doi:10.1111/1755-5922.12197.

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup